Detail akcie OraSure Tech online

Business Summary: OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, OraSure Technologies Inc revenues decreased 38% to $115M. Net loss increased from $19.5M to $68.7M. Revenues reflect Net product and services revenues - COVID-19 segment decrease of 99% to $624K, Net product and services revenues - HIV segment decrease of 18% to $49.8M, United States segment decrease of 44% to $78.3M, Africa (Region) segment decrease of 27% to $24M.